ABSTRACT
BRAF inhibitors have been licensed for the treatment of unresectable or metastatic BRAF-mutated melanomas. In Japan, the BRAF inhibitor vemurafenib has been available since December 2014. Several adverse events induced by BRAF inhibitors have been reported, such as Stevens-Johnson syndrome, toxic epidermal necrosis, squamous cell carcinoma, secondary melanoma, and hand-foot syndrome. Recently, inflammatory skin lesions clinically resembling erythema nodosum have been reported as side effects that may lead to treatment discontinuation. In this report, we described the first Japanese case of erythema nodosum-like lesions induced by vemurafenib and discussed the countermeasures to this adverse reaction. Dose reduction or interruption of BRAF inhibitors should be considered on a case-by-case basis because the condition may resolve spontaneously or under symptomatic treatment. We postulate that erythema nodosum-like lesions can be controlled by careful follow-up and supportive care.
